Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance
Authors
Keywords
-
Journal
Scientific Reports
Volume 5, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-09-30
DOI
10.1038/srep14538
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
- (2015) R. Pagliarini et al. EMBO REPORTS
- Therapy for myeloproliferative neoplasms: when, which agent, and how?
- (2014) H. L. Geyer et al. BLOOD
- A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
- (2014) Meenu Kesarwani et al. Jove-Journal of Visualized Experiments
- The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
- (2013) A. Heine et al. BLOOD
- Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon- in a murine model of polycythemia vera
- (2013) A. Mullally et al. BLOOD
- PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data
- (2013) Daniel R. Roe et al. Journal of Chemical Theory and Computation
- Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald
- (2013) Romelia Salomon-Ferrer et al. Journal of Chemical Theory and Computation
- Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
- (2012) A. Eghtedar et al. BLOOD
- JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
- (2012) A. Tefferi BLOOD
- Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
- (2012) S. Verstovsek et al. BLOOD
- Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
- (2012) Kathryn G. Roberts et al. CANCER CELL
- Converting Cancer Therapies into Cures: Lessons from Infectious Diseases
- (2012) Michael S. Glickman et al. CELL
- Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition
- (2012) Oliver Weigert et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
- (2012) Priya Koppikar et al. NATURE
- Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F
- (2012) Rajintha M Bandaranayake et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor
- (2012) Michael R. Marit et al. PLoS One
- JAK2 the future: therapeutic strategies for JAK-dependent malignancies
- (2012) Lindsay M. LaFave et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
- (2012) Rita Andraos et al. Cancer Discovery
- Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
- (2011) Wayne W. Chan et al. CANCER CELL
- The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers
- (2011) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Fast docking using the CHARMM force field with EADock DSS
- (2011) Aurélien Grosdidier et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms
- (2011) A Deshpande et al. LEUKEMIA
- Catalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms
- (2011) Natalia Jura et al. MOLECULAR CELL
- The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling
- (2011) Daniela Ungureanu et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- SwissDock, a protein-small molecule docking web service based on EADock DSS
- (2011) A. Grosdidier et al. NUCLEIC ACIDS RESEARCH
- Analysis of Jak2 Catalytic Function by Peptide Microarrays: The Role of the JH2 Domain and V617F Mutation
- (2011) Arturo Sanz et al. PLoS One
- CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
- (2010) J. W. Tyner et al. BLOOD
- Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease
- (2010) H. Akada et al. BLOOD
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
- (2010) Ann Mullally et al. CANCER CELL
- Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
- (2010) Jianming Zhang et al. NATURE
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- POLYVIEW-MM: web-based platform for animation and analysis of molecular simulations
- (2010) A. Porollo et al. NUCLEIC ACIDS RESEARCH
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- AP24163 Inhibits the Gatekeeper Mutant of BCR-ABL and SuppressesIn vitroResistance
- (2009) Mohammad Azam et al. Chemical Biology & Drug Design
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
- (2009) Garrett M. Morris et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- CHARMM: The biomolecular simulation program
- (2009) B. R. Brooks et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- Perspectives on the development of imatinib and the future of cancer research
- (2009) Brian J Druker NATURE MEDICINE
- Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera
- (2008) Gerlinde Wernig et al. CANCER CELL
- Oncogene Addiction
- (2008) I. B. Weinstein et al. CANCER RESEARCH
- Activation of tyrosine kinases by mutation of the gatekeeper threonine
- (2008) Mohammad Azam et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- SOCS regulation of the JAK/STAT signalling pathway
- (2008) Ben A. Croker et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- FACTS: Fast analytical continuum treatment of solvation
- (2007) Urs Haberthür et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started